Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

The vaccine contains inactivated antigens from four influenza virus strains. After injection, the immune system recognises these antigens and produces specific antibodies against the hemagglutinin and neuraminidase proteins, establishing active immunity that can neutralise the corresponding live viruses if encountered.

The dose and schedule of Influvac Tetra are determined by the prescribing healthcare professional based on the patient’s age, health status and local immunisation guidelines. The product is supplied as a single‑dose injectable solution for intramuscular or subcutaneous administration.

Safety data for Influvac Tetra in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits of influenza protection against any unknown risks and discuss the decision with the patient. The vaccine is not contraindicated, but professional guidance is recommended.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Influvac Tetra is a quadrivalent, inactivated vaccine covering two A subtypes and both B lineages, offering broader protection than trivalent formulations that omit one B strain. Compared with live‑attenuated nasal sprays, it is administered by injection and is suitable for a wider range of age groups and immunocompromised patients.

The vaccine must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to administration, allow the vial to reach room temperature for a short period if required by the label.

Influvac Tetra is supplied as a sterile injectable solution. A single dose is given by a trained healthcare professional via intramuscular injection, typically in the deltoid muscle, or subcutaneously if indicated. The injection site should be cleaned with an appropriate antiseptic before administration.

Serious adverse events are rare but can include anaphylaxis, Guillain‑Barré syndrome, severe allergic reactions, high‑grade fever, seizures, and myocarditis. Any signs of a severe reaction, such as difficulty breathing, swelling of the face or throat, or persistent high fever, require immediate medical attention.

Individuals with a known severe allergy to any component of the vaccine, or who have experienced a severe reaction to a previous influenza vaccine, should not receive Influvac Tetra. Persons with acute moderate or severe illness should defer vaccination until recovery. Consultation with a healthcare provider is essential for special populations.